Member Contact: Geoffrey Kempler
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
Prana Biotechnology is developing first-in-class therapies to treat orphan and non-orphan neurological diseases. The Company’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.